Navigation Links
Thoratec's ITC Division Receives FDA Warning Letter
Date:11/7/2007

Matter Involves Certain Lots of ProTime(R) Instruments

PLEASANTON, Calif., Nov. 7 /PRNewswire-FirstCall/ -- Thoratec Corporation (Nasdaq: THOR), a world leader in products to treat cardiovascular disease, said today that its International Technidyne Corporation (ITC) division has received a Warning Letter from the U.S. Food and Drug Administration (FDA) stating concerns about ITC's quality systems and specifically related to certain production lots of its ProTime System anticoagulation monitoring device.

The company said the Warning Letter relates to manufacturing and quality control issues involving a component from an outside supplier that could cause specific lots of the system to deliver error messages on the display instead of test results and/or the remote possibility of incorrect readings of patient blood coagulation levels.

ITC is scheduled to meet with FDA to discuss the Warning Letter and ITC's responses and believes that part of its corrective action will involve a voluntary recall of certain lots of its ProTime system, involving approximately 5,800 of the devices. ITC is not aware of any patient-related issues related to this matter. The company said that it believes the issue has been addressed and should not affect any future ProTime System shipments.

Management estimated that the cost of the product recall will be in the range of $0.5 million to $1.0 million and accordingly indicated that the company believes that this matter will have no impact on the company's financial guidance for fiscal 2007.

Thoratec is a world leader in therapies to address advanced stage heart failure. The company's product lines include the Thoratec VAD(R) (Ventricular Assist Device) and HeartMate(R) LVAS (Left Ventricular Assist System) with more than 11,000 devices implanted in patients suffering from heart failure. Additionally, its International Technidyne Corporation (ITC) division supplies blood testing and skin incision products. Thoratec is headquartered in Pleasanton, California. For more information, visit the company's web sites at http://www.thoratec.com or http://www.itcmed.com.

Many of the preceding paragraphs, particularly but not exclusively those addressing ITC product activities, fiscal guidance for 2007 financial results, and future performance contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These statements can be identified by the words, "believes," "expects," "could," "will," and other similar words. Actual results, events or performance could differ materially from these forward- looking statements based on a variety of factors, many of which are beyond Thoratec's control. Therefore, readers are cautioned not to put undue reliance on these statements. Investors are cautioned that all such statements involve risks and uncertainties, including risks related to regulatory decisions, the growth of existing markets for our products, changes in the mix of existing markets for our products and related gross margin for such product sales, the ability to improve financial performance, regulatory approval processes, the effects of healthcare reimbursement and coverage policies, the effects of seasonality in Thoratec products sales, the effects of price competition from any Thoratec competitors and the effects of any merger and acquisition related activities. Forward-looking statements contained in this press release should be considered in light of these factors and those factors discussed from time to time in Thoratec's public reports filed with the Securities and Exchange Commission, such as those discussed under the heading, "Risk Factors," in Thoratec's most recent annual report on Form 10-K and as may be updated in subsequent SEC filings. These forward-looking statements speak only as of the date hereof. Thoratec undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof, or to reflect the occurrence of unanticipated events.


'/>"/>
SOURCE Thoratec Corporation
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. HEI, Inc. Announces Sale of RFID Division Assets
2. QUANTEL Intends to Strengthen its Dermatology/ Aesthetics Division With the Acquisition of WaveLight Aesthetic GmbH
3. HEI, Inc. Closes on Sale of RFID Division Assets
4. Hooper Holmes Names Chris Behling President of Health & Wellness Division
5. Hooper Holmes Launches Health & Wellness Division at 2007 Disease Management Leadership Forum and Integrated Care Summit
6. Robert J. Heine, M.D., Ph.D., F.R.C.P. to Join Lilly; Distinguished Diabetes Expert to Lead Diabetes/Endocrine Medical Division
7. AHF Launches Public Health Division
8. Crdentias National Director of Travel Services Provides an Exclusive Interview on the Growth of Crdentias Travel Nurse Division
9. Global Med Technologies(R), Inc.s Division, Wyndgate Technologies(R), to Exhibit at 60th Annual AABB Conference
10. Dr. Stephen Paget, Physician-in-Chief and Chairman, Division of Rheumatology, at Hospital for Special Surgery is Available to Comment on a Recent CDC Study on the Impact of Arthritis in the Work Place
11. Bryan R. Rogers Appointed President of Far West Division
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... ... February 24, 2017 , ... ... University, has officially announced the appointment of Peter A. Bell, DO, MBA, HPF, ... Medicine (LUCOM), beginning April 10. Dr. Bell comes to Liberty from the ...
(Date:2/24/2017)... , ... February 24, 2017 , ... ... hearing disabilities, it is so critically important that we all are aware of ... is why Mediaplanet is proud to announce the launch of its newest edition ...
(Date:2/24/2017)... (PRWEB) , ... February 24, 2017 , ... With ProGlass ... Cut Pro X . Users have total control over position, rotation, distortion, edge softness, ... all within Final Cut Pro X. , With ProGlass Prism users are given the ...
(Date:2/24/2017)... ... ... The International Association of Eating Disorders Professionals (iaedp) announces the 2017 top five ... art competition. Selected from 15 submissions from around the nation, the top five finalists ... iaedp Symposium, March 22 – 26 in Las Vegas. , This year, the competition ...
(Date:2/24/2017)... ... February 24, 2017 , ... ... specializes in thought leadership , media relations, social media, content marketing and ... will be powered through Act-On, an intuitive marketing automation platform. , Rosica will ...
Breaking Medicine News(10 mins):
(Date:2/24/2017)...  This report analyzes the worldwide markets for Chiral ... Products: Intermediates, Analytical, and Others. The End Use ... Agrochemicals. The report provides separate comprehensive analytics for the ... , and Rest of World. Annual estimates and ... Also, a six-year historic analysis is provided for these ...
(Date:2/24/2017)... -- Medivir AB (Nasdaq Stockholm: MVIR) today ... of Directors that will be submitted to the 2017 ... of the company,s three largest shareholders at the end ... a seat on the Nomination Committee, and the Chairman ... Committee was as follows:  ...
(Date:2/23/2017)... Visiomed, the French leader in medical ... changing the landscape of healthcare with their innovative ... custom-made solutions. Recognizing the rising demand of self-monitoring ... without walls, Visiomed has launched BewellConnect, the most ... professionals that is empowering the lives of patients. ...
Breaking Medicine Technology: